Criteria:

Inclusion Criteria:
1. Age: 18 years and older
2. Sex: Male During the course of the study, from study screen until study exit, male
volunteers must use a spermicide-containing barrier method of contraception to
prevent the pregnancy of their sexual partner. This advice should be documented in
the informed consent form.
3. Weight: At least 60 kg (132 lbs) and all subjects within 15% of Ideal Body Weight
(IBW), as referenced by the Table of ""Desirable Weights of Adults"" Metropolitan
Life Insurance Company, 1999 (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE
PROTOCOLS).
4. All subjects should be judged normal and healthy during a pre-study medical
evaluation (physical examination, laboratory evaluation, Hepatitis B, Hepatitis C and
HIV tests, 12-lead ECG, and urine drug screen including amphetamine, barbiturates,
benzodiazepines, cannabinoid, cocaine, opiates, phencyclidine, and methadone)
performed within 14 days of the initial dose of study medication.
Exclusion Criteria:
1. Institutionalized subjects will not be used.
2. Social Habits:
1. Use of any tobacco products within one year prior to dosing.
2. Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage
within the 48 hours prior to the initial dose of study medication.
3. Ingestion of any vitamins or herbal products within 7 days prior to the initial
dose of the study medication.
4. Any recent, significant change in dietary or exercise habits.
3. Medications:
1. Use of any medication within the last 14 days prior to the initial dose of study
medication, including over-the-counter medications.
2. Use of any medication known to alter hepatic enzyme activity within 28 days
prior to the initial dose of study medication.
4. Diseases:
1. History of any significant chronic disease and/or hepatitis.
2. History of drug and/or alcohol abuse.
3. Acute illness at the time of either the pre-study medical evaluation or dosing.
4. A positive HIV, Hepatitis B, or Hepatitis C test result.
5. Abnormal and clinically significant laboratory test results:
1. Clinically significant deviation from the Guide to Clinically Relevant
Abnormalities (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).
2. Abnormal and clinically relevant ECG tracing.
6. Donation or loss of a significant volume of blood or plasma (> 450 mL) within 28 days
prior to the initial dose of study medication.
7. Subjects who have received an investigational drug within 30 days prior to the
initial dose of study medication.
8. Allergy or hypersensitivity to finasteride or other related products.
9. History of difficulties in swallowing, or any gastrointestinal disease which could
affect the drug absorption.
10. Consumption of grapefruit or grapefruit containing products within 7 days of drug
administration.

NCT ID:

NCT00650377

Primary Contact:

Principal InvestigatorDorian Williams, M.D.Kendle International Inc.

Backup Contact:

N/A

Location Contact:

Morgantown, West Virginia 26505United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.